医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BTIG to Host Inaugural China Biotech Day on Wednesday, June 1, 2022

2022年05月26日 PM09:30
このエントリーをはてなブックマークに追加


 

NEW YORK

BTIG announced today that it will hold an inaugural China Biotech Day, on Wednesday, June 1, 2022. This virtual event will include thematic panel discussions, fireside chats and one-on-one meetings. The conference will be hosted by:

  • Justin Zelin, BTIG Biotechnology Analyst
  • Bhavin Patel, PharmD, BTIG Healthcare Strategy & Franchise Sales Specialist
  • Kenny Storch, BTIG Healthcare Strategy & Franchise Sales Specialist
  • Isaac Boltansky, BTIG Director of Policy Research
  • Bert Hazlett, BTIG Biotechnology Analyst

Industry-leading biotechnology companies with operations in China will be participating in the firm’s conference. Management teams from each company will have an opportunity to directly connect with BTIG’s institutional investor clients. “The Chinese biotech sector is primed for growth due to accelerating drug development entering the global marketplace,” said Justin Zelin, BTIG Biotechnology Analyst. “Our event will provide a forum for BTIG’s institutional investor clients to explore emerging innovations, discuss latest trends, and see what’s on the horizon.”

More than 13 public and private biotechnology companies will be participating in the event. Panel discussion topics will include state of China biotech investments, cross border collaborations, China’s healthcare market and reimbursement, and accounting standards.

Mr. Zelin’s coverage specializes in cell therapy, targeted oncology, immunology and auto-immune disease therapeutics. Mr. Hazlett covers several therapeutic categories in the biotechnology sector, with a focus on CNS, oncology, rare disease and anti-infective companies. Their research with Mr. Boltansky’s policy analysis provide investors and companies a comprehensive perspective on biotechnology’s expanding economic impacts worldwide.

For more information about the conference, email info@btig.com. Please note that participants must be pre-registered to attend. To access BTIG insights, contact a firm representative or log in to www.btigresearch.com.

The conference is being produced by BTIG’s Corporate Access program which hosts client events across the consumer, energy and infrastructure, financials, healthcare, real estate and technology sectors.

About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 725 employees, BTIG, LLC and its affiliates operate out of 22 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.

Disclaimer: https://www.btig.com/disclaimer. To learn more about BTIG, visit www.btig.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005184/en/

CONTACT

Media:

Jill Gordon

443.668.2055

jgordon@prosek.com

Ariana Crupi

212.738.6142

acrupi@btig.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表